Curiox Biosystems
Key metrics
Earnings
| Revenue, Q3 2026 | ₩1.5bn |
|---|---|
| Revenue QoQ | +26.9% |
| Revenue YoY | +7.8% |
| Operating income, Q3 2026 | -₩3.9bn |
| Operating income QoQ | +12.2% |
| Operating income YoY | -46.1% |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | 0.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩0 |
| Buyback decided, last 12 months, % of shares | 0.0% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩0 |
| Treasury shares cancelled (number), last 12 months | 0 shares |
| Treasury shares cancelled, last 12 months, % of shares | 0.0% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 0 shares |
| Potential new shares, last 12 months | 0 shares |
| Potential new shares, % of shares | 0.0% |
| Conversion price adjustments, last 12 months | 0 |
Supply contracts
| Supply contracts, last 12 months | ₩0 |
|---|---|
| Supply contracts vs prior-year revenue | 0.0% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 10 |
|---|---|
| DART filings, previous 3 months | 8 |
Insider transactions
| Open-market buys, last 12 months (shares) | 0 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩0 |
| Open-market sells, last 12 months (shares) | 113,678 shares |
| Open-market sells, last 12 months (amount) | ₩5.2bn |
| Net open-market buying, last 12 months (shares) | -113,678 shares |
| Insiders who bought, last 12 months | 0 |
Insider transactions (last 12 months)
Open-market buys: 0 shares (₩0). Open-market sells: 113,678 shares (₩5.2bn). Net open-market buying: -113,678 shares. Insiders who bought: 0.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | Jung Hong-tae (Registered director) | Other (Stock option exercise) | +6,396 shares | ₩3,091 | ₩20m | |
| Nov 5, 2026 | Noh Hui-jun (Non-registered officer) | Other (Stock option exercise) | +900 shares | ₩4,416 | ₩4m | |
| Nov 5, 2026 | Noh Hui-jun (Non-registered officer) | Other (Stock option exercise) | +4,500 shares | ₩22,711 | ₩102m | |
| Nov 3, 2026 | Kim Nam-yong (Registered director, 10%+ shareholder) | Other (After-hours sell) | -570,000 shares | ₩45,942 | ₩26.2bn | |
| Aug 12, 2026 | Kim Nam-yong (Registered director, 10%+ shareholder) | Open-market sell | -105,500 shares | ₩42,723 | ₩4.5bn | |
| Aug 3, 2026 | Park Yeong-ho (Non-registered officer) | Other (Stock option exercise) | +3,000 shares | ₩4,416 | ₩13m | |
| Apr 9, 2026 | Jung Hong-tae (Registered director) | Open-market sell | -578 shares | ₩82,919 | ₩48m | |
| Apr 8, 2026 | Jung Hong-tae (Registered director) | Open-market sell | -4,400 shares | ₩80,987 | ₩356m | |
| Apr 7, 2026 | Jung Hong-tae (Registered director) | Open-market sell | -2,200 shares | ₩78,326 | ₩172m | |
| Apr 3, 2026 | Park Yeong-ho (Non-registered officer) | Other (Stock option exercise) | +9,096 shares | ₩7,729 | ₩70m | |
| Apr 3, 2026 | Park Seong-cheol (Non-registered officer) | Other (Stock option exercise) | +16,000 shares | ₩19,482 | ₩312m | |
| Apr 3, 2026 | Jung Hong-tae (Registered director) | Other (Stock option exercise) | +30,000 shares | ₩3,197 | ₩96m | |
| Apr 3, 2026 | Noh Hui-jun (Non-registered officer) | Other (Stock option exercise) | +1,164 shares | ₩4,416 | ₩5m | |
| Jan 7, 2026 | Noh Hui-jun (Non-registered officer) | Open-market sell | -1,000 shares | ₩115,625 | ₩116m | |
| Nov 25, 2025 | Noh Hui-jun (Non-registered officer) | Other (Stock option exercise) | +1,512 shares | ₩4,416 | ₩7m |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩5.2bn | -₩12.3bn |
| 2024 | ₩4.6bn | -₩13.4bn |
| 2023 | ₩6.8bn | -₩10.6bn |
Filing timeline
-
Curiox China Terminates ₩2.7bn HT and Buffer Exchanger Equipment Sales Contract
Curiox Biosystems filed notice that it terminated an equipment sales contract with its subsidiary Curiox Biosystems China Co., Ltd., effective Oct 29, 2026. The terminated contract amount was ₩2.7bn, reported as 37.6% of revenue. The company stated that it received an official letter from the upstream contractor saying performance of the contract was impossible.